David Hurewitz.

Bruce L. Zuraw, M.D treatments ., Paula J. Busse, M.D., Martha White, M.D., Joshua Jacobs, M.D., William Lumry, M.D., James Baker, M.D., Timothy Craig, D.O., J. Andrew Grant, M.D., David Hurewitz, M.D., Leonard Bielory, M.D., William. E. Cartwright, M.D., Majed Koleilat, M.D., Walter Ryan, D.O., Oren Schaefer, M.D., Michael Manning, M.D., Pragnesh Patel, M.D., Jonathan A. Bernstein, M.D., Roger A. Friedman, M.D., Robert Wilkinson, M.D., David Tanner, M.D., Gary Kohler, M.D., Glenne Gunther, M.D., Robyn Levy, M.D., James McClellan, M.D., Joseph Redhead, M.D., David Guss, M.D., Eugene Heyman, Ph.D., Brent A. Blumenstein, Ph.D., Ira Kalfus, M.D., and Michael M.

All authors vouch for the completeness and precision of the data and the analyses. The Cox proportional-hazards model was used to estimate hazard ratios and self-confidence intervals for the study outcomes comparing both intervention groups with the control group, while adjusting for prognostic baseline factors potentially. Data relating to infants who didn’t reach a study end point by 28 weeks were censored at the last negative HIV-1 check or at 28 weeks, whichever occurred 1st. To account for multiple comparisons with the control group, a P value of significantly less than 0.025 was considered to indicate statistical significance. Of the 463 women who have been ineligible, 289 got a CD4+ count of significantly less than either 200 cells or 250 cells per cubic millimeter .).). Based on the mother’s adherence record over five follow-up visits, infants received their recommended nevirapine doses an average of 94 percent of that time period, and mothers took their prescribed antiretroviral doses 89 percent of the time.